ClinConnect ClinConnect Logo
Search / Trial NCT06275542

Ability to Maintain Saturation Levels Without Oxygen Supplementation as a Extubation Criteria Without TOF Monitoring Equipment

Launched by UNIVERSITY OF SURABAYA · Feb 15, 2024

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Extubation Residual Paralysis Quantitative Tof Monitoring Reversal

ClinConnect Summary

The availability of Train-of-Four (TOF) monitoring devices is not yet widespread in some clinical practices. Practitioners are also often unaware of the high incidence of residual paralysis and the associated risks in their daily practice. However, residual paralysis increases the occurrence of airway obstruction, hypoxemia, and postoperative pulmonary complications. Therefore, clinical parameters for extubation criteria must ensure the absence of residual paralysis.

Administering oxygen in the ambient air can identify hypoventilation conditions. Therefore, patients who can maintain oxygen...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Elective surgery
  • 2. Adult patiens aged 18-60 years
  • 3. ASA physical status I-II
  • 4. Not receiving oxygen supplementation during pre-operative care
  • Exclusion Criteria:
  • 1. History of hypersensitivy or allergy to neostigmine, muscular blockade agents, or anesthetic agents given
  • 2. Head or neck surgery
  • 3. Inability to access the ulnar nerve for TOF measurement device placement
  • 4. History of lung diseases such asthma, COPD, or pleural effusion
  • 5. Hepatic impairment with liver enzyme values \> 50% of the normal range
  • 6. Renal insufficiency (serum creatinine \> 1.8 mg/dl) or kidney failure
  • 7. Patients with neuromuscular diseases
  • 8. Body mass index (BMI) \> 35 kg/m2
  • 9. Consumption of medications that affect neuromuscular transmission such as aminoglycoside, polymyxin, lincomycin, clindamycin, and tetracycline; local anesthetic agent, procainamide, quinidine, lithium, magnesium sulfate, furosemide, cyclosporine, dantrolene, anti-estrogens, anticonvulsant, calcium, steroid, and azathioprine.
  • 10. Patients with contraindications to neostigmine or atropine sulfate
  • 11. Planned post-operative intensive care unit treatment

About University Of Surabaya

The University of Surabaya is a leading academic institution dedicated to advancing research and education in the health sciences. As a clinical trial sponsor, the university is committed to conducting innovative studies that contribute to the understanding and treatment of various medical conditions. With a focus on ethical standards and regulatory compliance, the University of Surabaya collaborates with healthcare professionals and researchers to ensure the integrity and validity of its clinical trials. Through its multidisciplinary approach, the university aims to enhance patient outcomes and foster advancements in medical knowledge, making significant contributions to both local and global health initiatives.

Locations

Yogyakarta, , Indonesia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported